The news comes a day after the company decided to defer drug price increases for no more than six months, following criticism from U.S. President Donald Trump for raising list prices of some medicines. The units would be Innovative Medicines, Established Medicines and Consumer Healthcare. The company is currently split into two units – Innovative Medicines, which includes the consumer business, and Essential Health. …read more
Source:: Yahoo Finance
